Anti-orthopoxvirus recombinant polyclonal antibody
Disclosed is an anti-orthopoxvirus recombinant polyclonal antibody comprising distinct members which in union are capable of binding at least three orthopoxvirus related antigens, a pharmaceutical composition comprising the antibody, and a method for its production. Also disclosed is a polyclonal cell line capable of producing the recombinant polyclonal antibody as therapeutic methods utilizing the polyclonal antibody. Finally, the invention also pertains to a method for screening for useful V H and V L pairs useful when preparing the polyclonal antibody.
1. An anti-orthopoxvirus polyclonal recombinant antibody composition, comprising two or more distinct antibody molecules binding to different orthopoxvirus epitopes, wherein each distinct antibody comprises the following:
(a) a VH CDR1 selected from SEQ ID NOs: 50-138;
(b) a VH CDR2 selected from SEQ ID NOs: 139-227;
(c) a VH CDR3 selected from SEQ ID NOs: 228-316;
(d) a VL CDR1 selected from SEQ ID NOs: 317-405;
(e) a VL CDR2 selected from SEQ ID NOs: 406-494; and
(f) a VL CDR3 selected from SEQ ID NOs: 495-583;
wherein the CDRs are combined according to Table 5.
2. The composition of claim 1 , comprising two or more distinct antibody molecules binding to different epitopes of the same orthopoxvirus antigen.
3. The composition of claim 1 , comprising three or more distinct antibody molecules binding to three different orthopoxvirus antigens.
4. The composition of claim 3 , further comprising two or more distinct antibody molecules binding to different epitopes of the same orthopoxvirus antigen.
5. An anti-orthopoxvirus polyclonal recombinant antibody composition, comprising two or more antibodies selected from the group consisting of antibodies comprising heavy and light chain CDR1, CDR2, and CDR3 regions:
(a) SEQ ID NOs: 50, 139, 228, 317, 406, and 495;
(b) SEQ ID NOs: 52, 141, 230, 319, 408, and 497;
(c) SEQ ID NOs: 53, 142, 231, 320, 409 and 498;
(d) SEQ ID NOs: 54, 143, 232, 321, 410, and 499;
(e) SEQ ID NOs: 58, 147, 236, 325, 414, and 503;
(f) SEQ ID NOs: 66, 155, 244, 333, 422, and 511;
(g) SEQ ID NOs: 67, 156, 245, 334, 423 and 512;
(h) SEQ ID NOs: 69, 158, 247, 336, 425, and 514;
(i) SEQ ID NOs: 70, 159, 248, 337, 426, and 515;
(j) SEQ ID NOs: 72, 161, 250, 339, 428, and 517;
(k) SEQ ID NOs: 74, 163, 252, 341, 430, and 519;
(l) SEQ ID NOs: 79, 168, 257, 346, 435, and 524;
(m) SEQ ID NOs: 81, 170, 259, 348, 437 and 526;
(n) SEQ ID NOs: 92, 181, 270, 359, 448, and 537;
(o) SEQ ID NOs: 96, 185, 274, 363, 452, and 541;
(p) SEQ ID NOs: 99, 188, 277, 366, 455, and 544;
(q) SEQ ID NOs: 101, 190, 279, 368, 457, and 546;
(r) SEQ ID NOs: 107, 196, 285, 374, 463, and 552;
(s) SEQ ID NOs: 108, 197, 286, 375, 464 and 553;
(t) SEQ ID NOs: 109, 198, 287, 376, 465, and 554;
(u) SEQ ID NOs: 114, 203, 292, 381, 470, and 559;
(v) SEQ ID NOs: 117, 206, 295, 384, 473, and 562;
(w) SEQ ID NOs: 121, 210, 299, 388, 477, and 566;
(x) SEQ ID NOs: 122, 211, 300, 389, 478, and 567;
(y) SEQ ID NOs: 123, 212, 301, 390, 479, and 568; and
(z) SEQ ID NOs: 132, 221, 310, 399, 488, and 577.
6. An anti-orthopoxvirus polyclonal recombinant antibody composition, comprising antibodies comprising heavy and light chain CDR1, CDR2, and CDR3 regions:
(a) SEQ ID NOs: 57, 146, 235, 324, 413, and 502; and
(b) SEQ ID NOs: 78, 167, 256, 345, 434, and 523.